You are here

liver cancer

Bristol Myers Squibb snags new liver cancer nod for Opdivo-Yervoy combo

Bristol Myers Squibb snags new liver cancer nod for Opdivo-Yervoy combo

Fierce Pharma

Bristol-Myers Squibb

hepatocellular carcinoma

Flag link:

Roche shows Tecentriq/Avastin combo helps liver cancer patients live longer

Roche shows Tecentriq/Avastin combo helps liver cancer patients live longer

Endpoints

clinical trials

Flag link:

Breakthrough status and promise of a speedy review arrives for Opdivo/Yervoy combination as Bristol-Myers bites at Bayer

Breakthrough status and promise of a speedy review arrives for Opdivo/Yervoy combination as Bristol-Myers bites at Bayer

Endpoints

Bristol-Myers Squibb

Flag link:

Roche's Tecentriq scores a first-in-class double win in new liver cancer patients

Roche's Tecentriq scores a first-in-class double win in new liver cancer patients

Fierce Pharma

immuno-oncology

Flag link:

Exelixis Hits Blockbuster Status

Exelixis Hits Blockbuster Status

Motley Fool

Flag link:

Bristol-Myers star Opdivo fails survival test in a matchup with Nexavar aimed at shaking up the big HCC market

Bristol-Myers star Opdivo fails survival test in a matchup with Nexavar aimed at shaking up the big HCC market

Endpoints

Bristol-Myers Squibb

clinical trials

Flag link:

Lilly gets fifth use for Cyramza with FDA liver cancer nod

Lilly gets fifth use for Cyramza with FDA liver cancer nod

Pharmaforum

hepatocellular carcinoma

Flag link:

After a delay, Can-Fite digs into subpopulation data as liver cancer drug fails to hit primary endpoint

After a delay, Can-Fite digs into subpopulation data as liver cancer drug fails to hit primary endpoint

Fierce Biotech

Can-Fite BioPharma

clinical trials

Flag link:

Merck’s PhIII liver cancer study for Keytruda fails on two key endpoints, just three months after the FDA gave it the green light

Merck’s PhIII liver cancer study for Keytruda fails on two key endpoints, just three months after the FDA gave it the green light

Endpoints

clinical trials

Flag link:

Anti-rejection drug rapamycin shows promise in liver cancer

Anti-rejection drug rapamycin shows promise in liver cancer

Fierce Biotech

mTOR inhibitors

Flag link:

FDA approves Cabometyx for liver cancer

FDA approves Cabometyx for liver cancer

BioCentury

Flag link:

Merck gets FDA okay for Keytruda as liver cancer therapy

Merck gets FDA okay for Keytruda as liver cancer therapy

Pharmaforum

hepatocellular carcinoma

Flag link:

Eisai and Merck Announce China Approval of Lenvima for Treatment of Unresectable Hepatocellular Carcinoma

Eisai and Merck Announce China Approval of Lenvima for Treatment of Unresectable Hepatocellular Carcinoma

CP Wire

Flag link:

Eisai and Merck Announce China Approval of Lenvima for Treatment of Unresectable Hepatocellular Carcinoma

hepatocellular carcinoma

Flag link:

Death rate from liver cancer skyrockets

Death rate from liver cancer skyrockets

WWSB

Flag link:

Japan's Eisai sets price tag of about $16,000 on liver cancer drug

Japan's Eisai sets price tag of about $16,000 on liver cancer drug

Yahoo/Reuters

Flag link:

FDA stalls Eisai—and its new partner Merck—in quest to widen cancer med Lenvima's reach

FDA stalls Eisai—and its new partner Merck—in quest to widen cancer med Lenvima's reach

Fierce Pharma

Flag link:

Lilly's Cyramza succeeds in late-stage liver cancer trial

Lilly's Cyramza succeeds in late-stage liver cancer trial

Yahoo/Reuters

clinical trials

Flag link:

Bristol-Myers' I-O star Opdivo steps up to challenge Bayer's Stivarga in liver cancer

Bristol-Myers' I-O star Opdivo steps up to challenge Bayer's Stivarga in liver cancer

Fierce Pharma

Bristol-Myers Squibb

Flag link:

Eisai's Lenvima nabs survival edge in liver cancer showdown with Bayer's Nexavar

Eisai's Lenvima nabs survival edge in liver cancer showdown with Bayer's Nexavar

Fierce Pharma

Flag link:

Pages